R. Summers, D. Switz, J. Sessions, and . Jr, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, vol.77, pp.847-69, 1979.

P. Rutgeerts, R. Lofberg, and H. Malchow, A Comparison of Budesonide with Prednisolone for Active Crohn's Disease, New England Journal of Medicine, vol.331, issue.13, pp.842-847, 1994.
DOI : 10.1056/NEJM199409293311304

W. Sandborn, B. Feagan, and S. Hanauer, A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease, Gastroenterology, vol.122, issue.2, pp.512-542, 2002.
DOI : 10.1053/gast.2002.31072

P. Munkholm, E. Langholz, M. Davidsen, and V. Binder, Frequency of glucocorticoid resistance and dependency in Crohn's disease., Gut, vol.35, issue.3, pp.360-362, 1994.
DOI : 10.1136/gut.35.3.360

J. Markowitz, K. Grancher, N. Kohn, M. Lesser, and F. Daum, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, vol.119, issue.4
DOI : 10.1053/gast.2000.18144

S. Hanauer, Considerations in the management of steroiddependent Crohn's disease, Gastroenterology, vol.125, pp.906-916, 2003.

J. Kjeldsen, Treatment of Ulcerative Colitis with High Doses of Oral Prednisolone : The Rate of Remission, the Need for Surgery, and the Effect of Prolonging the Treatment, Scandinavian Journal of Gastroenterology, vol.88, issue.9, pp.821-827, 1993.
DOI : 10.1136/bmj.1.5119.387

W. Faubion, . Jr, E. Loftus, . Jr, W. Harmsen et al., The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study, Gastroenterology, vol.121, issue.2, pp.255-60, 2001.
DOI : 10.1053/gast.2001.26279

G. Elion, The Pharmacology of Azathioprine, Annals of the New York Academy of Sciences, vol.9, issue.1 Immunomodulat, pp.401-408, 1993.
DOI : 10.1021/jm00127a013

I. Tiede, G. Fritz, and S. Strand, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes, Journal of Clinical Investigation, vol.111, issue.8, pp.1133-1178, 2003.
DOI : 10.1172/JCI16432

D. Tidd and A. Paterson, A biochemical mechanism for delayed cytotoxic reaction of 6-mercaptopurine, Cancer Res, vol.34, pp.738-784, 1974.

R. Weinshilboum and S. Siadek, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet, vol.32, pp.651-61, 1980.

M. Dubinsky, H. Yang, and P. Hassard, 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease, Gastroenterology, vol.122, issue.4
DOI : 10.1053/gast.2002.32420

A. Ansari, S. Soon, and M. Arenas, Thiopurine methyltransferase activity predicts both toxicity and clinical response to azathioprine in inflammatory bowel disease: The London IBD Forum Prospective study, Gastroenterology, vol.126, p.1293, 2004.

C. Cuffari, S. Hunt, and T. Bayless, Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease, Gut, vol.48, issue.5, pp.642-648, 2001.
DOI : 10.1136/gut.48.5.642

M. Dubinski, S. Lamothe, and S. Hy, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology, vol.118, issue.4, pp.705-718, 2000.
DOI : 10.1016/S0016-5085(00)70140-5

C. Cuffari, T. Dassopoulos, L. Turnbough, R. Thompson, and T. Bayless, Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease, Clinical Gastroenterology and Hepatology, vol.2, issue.5, pp.410-417, 2004.
DOI : 10.1016/S1542-3565(04)00127-2

P. Lowry, C. Franklin, and A. Weaver, Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease, Gut, vol.49, issue.5, pp.665-70, 2001.
DOI : 10.1136/gut.49.5.665

J. Belaiche, J. Desager, Y. Horsmans, and E. Louis, Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease, Scandinavian Journal of Gastroenterology, vol.36, issue.1, pp.71-77, 2001.
DOI : 10.1080/00365520150218084

C. Gasche, J. Scholmerich, and J. Brynskov, A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Inflamm Bowel Dis, vol.6, pp.8-15, 1998.

S. Plevy, Corticosteroid-sparing treatments in patients with Crohn's disease, The American Journal of Gastroenterology, vol.39, issue.2, pp.1607-1624, 2002.
DOI : 10.1016/S0140-6736(97)80083-9

L. Lennard, Clinical Implications of Thiopurine Methyltransferase-Optimization of Drug Dosage and Potential Drug Interactions, Therapeutic Drug Monitoring, vol.20, issue.5, pp.527-558, 1998.
DOI : 10.1097/00007691-199810000-00014

P. Lowry, C. Franklin, and A. Weaver, Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide, Gut, vol.49, issue.5, pp.656-64, 2001.
DOI : 10.1136/gut.49.5.656

L. Lennard and J. Maddocks, Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells, Journal of Pharmacy and Pharmacology, vol.229, issue.1, pp.15-23, 1983.
DOI : 10.1111/j.2042-7158.1983.tb04255.x

B. Bonaz, J. Boitard, and P. Marteau, Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine, Alimentary Pharmacology and Therapeutics, vol.18, issue.4, pp.401-409, 2003.
DOI : 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5

X. Roblin, F. Serre-debeauvais, J. Phelip, G. Bessard, and B. Bonaz, Drug interaction between infliximab and azathioprine in patients with Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.39, issue.9, pp.917-942, 2003.
DOI : 10.1016/S0140-6736(02)08512-4

A. Rossi, M. Bianchi, C. Garnieri, R. Barale, and G. Pacifici, Genotype???phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects, European Journal of Clinical Pharmacology, vol.57, issue.1, pp.51-55, 2001.
DOI : 10.1007/s002280000246

E. Zietkiewicz, V. Yotova, and M. Jarnik, Nuclear DNA diversity in worldwide distributed human populations, Gene, vol.205, issue.1-2, pp.161-71, 1997.
DOI : 10.1016/S0378-1119(97)00408-3

W. Best, J. Becktel, J. Singleton, and F. Kern, Development of a Crohn's disease activity index, Gastroenterology, vol.70, pp.439-483, 1976.

L. Sutherland, F. Martin, and S. Greer, 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis, Gastroenterology, vol.92, issue.6, pp.1894-1902, 1987.
DOI : 10.1016/0016-5085(87)90621-4

S. Lichtiger, D. Present, and A. Kornbluth, Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

R. Modigliani, J. Mary, and J. Simon, Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Gastroenterology, vol.98, issue.4, pp.811-819, 1990.
DOI : 10.1016/0016-5085(90)90002-I

K. Ewe, A. Press, and C. Singe, Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease, Gastroenterology, vol.105, issue.2, pp.367-72, 1993.
DOI : 10.1016/0016-5085(93)90709-L

S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig et al., A controlled double blind study of azathioprine in the management of Crohn's disease., Gut, vol.37, issue.5, pp.674-682, 1995.
DOI : 10.1136/gut.37.5.674

D. Present, B. Korelitz, N. Wisch, J. Glass, D. Sachar et al., Treatment of Crohn's Disease with 6-Mercaptopurine, New England Journal of Medicine, vol.302, issue.18, pp.981-988, 1980.
DOI : 10.1056/NEJM198005013021801

D. Pearson, G. May, G. Fick, and L. Sutherland, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

G. Mantzaris, M. Sfakianakis, and E. Archavlis, A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis, The American Journal of Gastroenterology, vol.119, issue.6, pp.1122-1130, 2004.
DOI : 10.1136/gut.49.5.656

A. Lopez-sanroman, F. Bermejo, E. Carrera, and A. Garcia-plaza, Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.122, issue.2, pp.161-167, 2004.
DOI : 10.1136/gut.48.5.642

C. Thomas, . Jr, P. Lowry, and C. Franklin, Erythrocyte Mean Corpuscular Volume as a Surrogate Marker for 6-Thioguanine Nucleotide Concentration Monitoring in Patients with Inflammatory Bowel Disease Treated with Azathioprine or 6-Mercaptopurine, Inflammatory Bowel Diseases, vol.9, issue.4, pp.237-282, 2003.
DOI : 10.1097/00054725-200307000-00004

B. Feagan, R. Fedorak, and E. Irvine, A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease, New England Journal of Medicine, vol.342, issue.22, pp.1627-1659, 2000.
DOI : 10.1056/NEJM200006013422202

M. 41-lemann, J. Colombel, B. Duclos, M. Veyrac, J. Dupas et al., Infliximab in steroid dependent Crohn's disease patients treated with azathioprine or mercaptopurine. A randomized double-blind placebo controlled trial, Gastroenterology, vol.124, p.602, 2003.

A. Fraser, T. Orchard, and D. Jewell, The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review, Gut, vol.50, issue.4, pp.485-494, 2002.
DOI : 10.1136/gut.50.4.485

A. Marinaki, A. Ansari, and J. Duley, Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase), Pharmacogenetics, vol.14, issue.3, pp.181-188, 2004.
DOI : 10.1097/00008571-200403000-00006

A. Ansari, C. Hassan, and J. Duley, Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.46, issue.4, pp.1743-50, 2002.
DOI : 10.1046/j.1365-2036.2002.01156.x